GARDP, WHO, ICMR to collaborate for studying sepsis & AMR
Global Antibiotic Research and Development Partnership (GARDP), the World Health Organization (WHO) and Indian Council of Medical Research (ICMR) recently organised an event on reducing neonatal and child mortality by addressing drug resistance through collaboration, research, and innovation. More than 80 researchers from 11 countries met in New Delhi to kick off an observational study to understand sepsis in newborns and current antibiotic prescribing practices. This is part of the GARDP’s broader programme to develop new and improved antibiotic treatments for newborns. The observational study, led by the GARDP, is benefiting from $2 million funding from Bill & Melinda Gates Foundation to support study sites in Bangladesh, India, Kenya, South Africa, and Uganda. The study will generate a robust evidence base on how neonatal sepsis is managed which can be used as a basis for evaluating future interventions in neonates. Outcomes of interest will include mortality, antibiotic use, and duration of antimicrobial therapy.